Pan-Cancer Transcriptomic Analysis Identifies PLK1 Crucial for the Tumorigenesis of Clear Cell Renal Cell Carcinoma

References

• Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas (TCGA) Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455(7216):1061–1068. doi:10.1038/nature07385
   PubMed Web of Science ®Google Scholar
• Barretina J, Caponigro G, Stransky N, et al. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483(7391):603–607. doi:10.1038/nature11003
   PubMed Web of Science ®Google Scholar
• Blum A, Wang P, Zenklusen JC. SnapShot: TCGA-analyzed tumors. Cell. 2018;173(2):530. doi:10.1016/j.cell.2018.03.059
   PubMed Web of Science ®Google Scholar
• Hutter C, Zenklusen JC. The cancer genome atlas: creating lasting value beyond its data. Cell. 2018;173(2):283–285. doi:10.1016/j.cell.2018.03.042
   PubMed Web of Science ®Google Scholar
• Weinstein JN, Collisson EA, Mills GB, et al. The cancer genome atlas pan-cancer analysis project. Nat Genet. 2013;45(10):1113–1120. doi:10.1038/ng.2764
   PubMed Web of Science ®Google Scholar
• Golsteyn RM, Lane HA, Mundt KE, Arnaud L, Nigg EA. The family of polo-like kinases. Prog Cell Cycle Res. 1996;2:107–114. doi:10.1007/978-1-4615-5873-6_11
   PubMedGoogle Scholar
• Lens SM, Voest EE, Medema RH. Shared and separate functions of polo-like kinases and Aurora kinases in cancer. Nat Rev Cancer. 2010;10(12):825–841. doi:10.1038/nrc2964
   PubMed Web of Science ®Google Scholar
• Shakeel I, Basheer N, Hasan GM, Afzal M, Hassan MI. Polo-like Kinase 1 as an emerging drug target: structure, function and therapeutic implications. J Drug Target. 2021;29(2):168–184.
   PubMed Web of Science ®Google Scholar
• Montaudon E, Nikitorowicz-Buniak J, Sourd L, et al. PLK1 inhibition exhibits strong anti-tumoral activity in CCND1-driven breast cancer metastases with acquired palbociclib resistance. Nat Commun. 2020;11(1):4053. doi:10.1038/s41467-020-17697-1
   PubMed Web of Science ®Google Scholar
• Shin CH, Lee H, Kim HR, Choi KH, Joung JG, Kim HH. Regulation of PLK1 through competition between hnRNPK, miR-149-3p and miR-193b-5p. Cell Death Differ. 2017;24(11):1861–1871. doi:10.1038/cdd.2017.106
   PubMed Web of Science ®Google Scholar
• Zhu J, Cui K, Cui Y, Ma C, Zhang Z. PLK1 knockdown inhibits cell proliferation and cell apoptosis, and PLK1 is negatively regulated by miR-4779 in osteosarcoma cells. DNA Cell Biol. 2020;39(5):747–755. doi:10.1089/dna.2019.5002
   PubMed Web of Science ®Google Scholar
• Wang B, Huang X, Liang H, et al. PLK1 inhibition sensitizes breast cancer cells to radiation via suppressing autophagy. Int J Radiat Oncol Biol Phys. 2021;110(4):1234–1247. doi:10.1016/j.ijrobp.2021.02.025
   PubMed Web of Science ®Google Scholar
• Colaprico A, Silva TC, Olsen C, et al. TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res. 2016;44(8):e71. doi:10.1093/nar/gkv1507
   PubMed Web of Science ®Google Scholar
• Ghandi M, Huang FW, Jané-Valbuena J, et al. Next-generation characterization of the cancer cell line encyclopedia. Nature. 2019;569(7757):503–508. doi:10.1038/s41586-019-1186-3
   PubMed Web of Science ®Google Scholar
• Lonsdale J, Thomas J, Salvatore M, et al. The Genotype-Tissue Expression (GTEx) project. Nat Genet. 2013;45(6):580–585. doi:10.1038/ng.2653
   PubMed Web of Science ®Google Scholar
• Han X, Zhou Z, Fei L, et al. Construction of a human cell landscape at single-cell level. Nature. 2020;581(7808):303–309. doi:10.1038/s41586-020-2157-4
   PubMed Web of Science ®Google Scholar
• Clark DJ, Dhanasekaran SM, Petralia F, et al. Integrated proteogenomic characterization of clear cell renal cell carcinoma. Cell. 2019;179(4):964–983.e931. doi:10.1016/j.cell.2019.10.007
   PubMed Web of Science ®Google Scholar
• Jiang Z, Yin W, Zhu H, et al. METTL7B is a novel prognostic biomarker of lower-grade glioma based on pan-cancer analysis. Cancer Cell Int. 2021;21(1):383. doi:10.1186/s12935-021-02087-4
   PubMed Web of Science ®Google Scholar
• Zhou B, Gao S. Pan-cancer analysis of FURIN as a potential prognostic and immunological biomarker. Front Mol Biosci. 2021;8:648402. doi:10.3389/fmolb.2021.648402
   PubMed Web of Science ®Google Scholar
• Li T, Fan J, Wang B, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77(21):e108–e110. doi:10.1158/0008-5472.CAN-17-0307
   PubMed Web of Science ®Google Scholar
• Xu WX, Zhang J, Hua YT, Yang SJ, Wang DD, Tang JH. An integrative pan-cancer analysis revealing LCN2 as an oncogenic immune protein in tumor microenvironment. Front Oncol. 2020;10:605097. doi:10.3389/fonc.2020.605097
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zheng J. Functions of immune checkpoint molecules beyond immune evasion. Adv Exp Med Biol. 2020;1248:201–226.
   PubMed Web of Science ®Google Scholar
• Allgäuer M, Budczies J, Christopoulos P, et al. Implementing tumor mutational burden (TMB) analysis in routine diagnostics-a primer for molecular pathologists and clinicians. Trans Lung Cancer Res. 2018;7(6):703–715. doi:10.21037/tlcr.2018.08.14
   PubMed Web of Science ®Google Scholar
• Choucair K, Morand S, Stanbery L, Edelman G, Dworkin L, Nemunaitis J. TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials. Cancer Gene Ther. 2020;27(12):841–853. doi:10.1038/s41417-020-0174-y
   PubMed Web of Science ®Google Scholar
• van Velzen MJM, Derks S, van Grieken NCT, Haj Mohammad N, van Laarhoven HWM. MSI as a predictive factor for treatment outcome of gastroesophageal adenocarcinoma. Cancer Treat Rev. 2020;86:102024. doi:10.1016/j.ctrv.2020.102024
   PubMed Web of Science ®Google Scholar
• Oliveira AF, Bretes L, Furtado I. Review of PD-1/PD-L1 inhibitors in metastatic dMMR/MSI-H colorectal cancer. Front Oncol. 2019;9:396. doi:10.3389/fonc.2019.00396
   PubMed Web of Science ®Google Scholar
• Huang Y, Li GM. DNA mismatch repair in the context of chromatin. Cell Biosci. 2020;10(1):10. doi:10.1186/s13578-020-0379-7
   PubMed Web of Science ®Google Scholar
• Parry A, Rulands S, Reik W. Active turnover of DNA methylation during cell fate decisions. Nat Rev Genet. 2021;22(1):59–66. doi:10.1038/s41576-020-00287-8
   PubMed Web of Science ®Google Scholar
• Dufies M, Verbiest A, Cooley LS, et al. Plk1, upregulated by HIF-2, mediates metastasis and drug resistance of clear cell renal cell carcinoma. Commun Biol. 2021;4(1):166. doi:10.1038/s42003-021-01653-w
   PubMed Web of Science ®Google Scholar
• Gao Z, Man X, Li Z, et al. PLK1 promotes proliferation and suppresses apoptosis of renal cell carcinoma cells by phosphorylating MCM3. Cancer Gene Ther. 2020;27(6):412–423. doi:10.1038/s41417-019-0094-x
   PubMed Web of Science ®Google Scholar
• Zhang G, Zhang Z, Liu Z. Polo-like kinase 1 is overexpressed in renal cancer and participates in the proliferation and invasion of renal cancer cells. Tumor Biol. 2013;34(3):1887–1894. doi:10.1007/s13277-013-0732-0
   PubMedGoogle Scholar
• Ding Y, Huang D, Zhang Z, et al. Combined gene expression profiling and RNAi screening in clear cell renal cell carcinoma identify PLK1 and other therapeutic kinase targets. Cancer Res. 2011;71(15):5225–5234. doi:10.1158/0008-5472.CAN-11-0076
   PubMed Web of Science ®Google Scholar
• Yang F, Wu Q, Zhang Y, et al. LncRNA LOC653786 promotes growth of RCC cells via upregulating FOXM1. Oncotarget. 2018;9(15):12101–12111. doi:10.18632/oncotarget.24027
   PubMedGoogle Scholar
• Jiang Y, Zhang H, Li W, Yan Y, Yao X, Gu W. FOXM1-activated LINC01094 promotes clear cell renal cell carcinoma development via microRNA 224-5p/CHSY1. Mol Cell Biol. 2020;40(3). doi:10.1128/MCB.00357-19
   Web of Science ®Google Scholar
• Okato A, Arai T, Yamada Y, et al. Dual strands of pre-miR-149 inhibit cancer cell migration and invasion through targeting FOXM1 in renal cell carcinoma. Int J Mol Sci. 2017;18(9):1969. doi:10.3390/ijms18091969
   PubMed Web of Science ®Google Scholar
• Kelleher FC, O’Sullivan H. FOXM1 in sarcoma: role in cell cycle, pluripotency genes and stem cell pathways. Oncotarget. 2016;7(27):42792–42804. doi:10.18632/oncotarget.8669
   PubMedGoogle Scholar
• Sakurai Y, Hatakeyama H, Akita H, Harashima H. Improvement of doxorubicin efficacy using liposomal anti-polo-like kinase 1 siRNA in human renal cell carcinomas. Mol Pharm. 2014;11(8):2713–2719. doi:10.1021/mp500245z
   PubMed Web of Science ®Google Scholar
• Fu Z, Malureanu L, Huang J, et al. Plk1-dependent phosphorylation of FoxM1 regulates a transcriptional programme required for mitotic progression. Nat Cell Biol. 2008;10(9):1076–1082. doi:10.1038/ncb1767
   PubMed Web of Science ®Google Scholar
• Holtrich U, Wolf G, Bräuninger A, et al. Induction and down-regulation of PLK, a human serine/threonine kinase expressed in proliferating cells and tumors. Proc Natl Acad Sci U S A. 1994;91(5):1736–1740. doi:10.1073/pnas.91.5.1736
   PubMed Web of Science ®Google Scholar
• Zhang Z, Zhang G, Kong C. High expression of polo-like kinase 1 is associated with the metastasis and recurrence in urothelial carcinoma of bladder. Urol Oncol. 2013;31(7):1222–1230. doi:10.1016/j.urolonc.2011.11.028
   PubMed Web of Science ®Google Scholar
• Takahashi T, Sano B, Nagata T, et al. Polo-like kinase 1 (PLK1) is overexpressed in primary colorectal cancers. Cancer Sci. 2003;94(2):148–152. doi:10.1111/j.1349-7006.2003.tb01411.x
   PubMed Web of Science ®Google Scholar
• Knecht R, Elez R, Oechler M, Solbach C, von Ilberg C, Strebhardt K. Prognostic significance of polo-like kinase (PLK) expression in squamous cell carcinomas of the head and neck. Cancer Res. 1999;59(12):2794–2797.
   PubMed Web of Science ®Google Scholar
• Ito Y, Miyoshi E, Sasaki N, et al. Polo-like kinase 1 overexpression is an early event in the progression of papillary carcinoma. Br J Cancer. 2004;90(2):414–418. doi:10.1038/sj.bjc.6601540
   PubMed Web of Science ®Google Scholar
• Brandwein JM. Targeting polo-like kinase 1 in acute myeloid leukemia. Ther Adv Hematol. 2015;6(2):80–87. doi:10.1177/2040620715571077
   PubMedGoogle Scholar
• Zhang XG, Lu XF, Jiao XM, Chen B, Wu JX. PLK1 gene suppresses cell invasion of undifferentiated thyroid carcinoma through the inhibition of CD44v6, MMP-2 and MMP-9. Exp Ther Med. 2012;4(6):1005–1009. doi:10.3892/etm.2012.729
   PubMed Web of Science ®Google Scholar
• Otsu H, Iimori M, Ando K, et al. Gastric cancer patients with high PLK1 expression and DNA aneuploidy correlate with poor prognosis. Oncology. 2016;91(1):31–40. doi:10.1159/000445952
   PubMed Web of Science ®Google Scholar
• Cebrián A, Gómez Del Pulgar T, Fernández-Aceñero MJ, et al. Decreased PLK1 expression denotes therapy resistance and unfavourable disease-free survival in rectal cancer patients receiving neoadjuvant chemoradiotherapy. Pathol Res Pract. 2016;212(12):1133–1137. doi:10.1016/j.prp.2016.09.012
   PubMed Web of Science ®Google Scholar
• Liu W, Ye H, Liu YF, et al. Transcriptome-derived stromal and immune scores infer clinical outcomes of patients with cancer. Oncol Lett. 2018;15(4):4351–4357. doi:10.3892/ol.2018.7855
   PubMed Web of Science ®Google Scholar
• Kaderbhaï C, Tharin Z, Ghiringhelli F. The role of molecular profiling to predict the response to immune checkpoint inhibitors in lung cancer. Cancers. 2019;11(2):201. doi:10.3390/cancers11020201
   PubMed Web of Science ®Google Scholar
• Xu WH, Xu Y, Wang J, et al. Prognostic value and immune infiltration of novel signatures in clear cell renal cell carcinoma microenvironment. Aging. 2019;11(17):6999–7020. doi:10.18632/aging.102233
   PubMedGoogle Scholar
• Rini BI, Battle D, Figlin RA, et al. The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC). J Immunother Cancer. 2019;7(1):354. doi:10.1186/s40425-019-0813-8
   PubMed Web of Science ®Google Scholar
• Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science. 2013;342(6165):1432–1433. doi:10.1126/science.342.6165.1432
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803–1813. doi:10.1056/NEJMoa1510665
   PubMed Web of Science ®Google Scholar
• Xu W, Atkins MB, McDermott DF. Checkpoint inhibitor immunotherapy in kidney cancer. Nat Rev Urol. 2020;17(3):137–150. doi:10.1038/s41585-020-0282-3
   PubMed Web of Science ®Google Scholar
• Samstein RM, Lee CH, Shoushtari AN, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019;51(2):202–206. doi:10.1038/s41588-018-0312-8
   PubMed Web of Science ®Google Scholar
• Martincorena I, Campbell PJ. Somatic mutation in cancer and normal cells. Science. 2015;349(6255):1483–1489. doi:10.1126/science.aab4082
   PubMed Web of Science ®Google Scholar
• Fishel R. Mismatch repair. J Biol Chem. 2015;290(44):26395–26403. doi:10.1074/jbc.R115.660142
   PubMed Web of Science ®Google Scholar
• Klutstein M, Nejman D, Greenfield R, Cedar H. DNA methylation in cancer and aging. Cancer Res. 2016;76(12):3446–3450. doi:10.1158/0008-5472.CAN-15-3278
   PubMed Web of Science ®Google Scholar